Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

NCT03280667 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma, Clear Cell
Metastatic Kidney Cancer

Interventions

DRUG: Pembrolizumab plus denosumab

Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Collaborators

[object Object]
[object Object]